Affymax (AFFY) wins approval for its drug to treat anemic kidney patients -Bloomberg
Affymax (Nasdaq: AFFY) wins approval for its drug to treat anemic kidney patients
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stemline Therapeutics' (STML) SL-701 Receives FDA Orphan Designation as Glioma Treatment
- Gulf Resources (GURE) Mentioned Catiously at White Diamond
- Aegis Capital Adjusts PT on Stemline (STML) to $55 Following Financing, Development Update
Create E-mail Alert Related CategoriesFDA, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!